Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

46.90CHF
14 Nov 2018
Change (% chg)

-- (--)
Prev Close
CHF46.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
69,829
52-wk High
CHF81.45
52-wk Low
CHF44.02

Latest Key Developments (Source: Significant Developments)

Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib
Tuesday, 17 Apr 2018 

April 17 (Reuters) - ArQule Inc ::ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA.ARQULE INC - UNDER TERMS OF AGREEMENT, ARQULE WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION.ARQULE INC - ARQULE ELIGIBLE TO RECEIVE UP TO $336 MILLION INCLUDING UPFRONT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.ARQULE - UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY.ARQULE - ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION.ARQULE - BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY.  Full Article

Basilea Announces Completion Of License Agreement Extension With Pfizer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC.  Full Article

Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Basilea Pharmaceutica Ag ::‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​.‍BASILEA EXPECTS TO COMPLETE PHASE 1 PATIENT RECRUITMENT INTO SEPARATE GLIOBLASTOMA ARM OF ORAL STUDY IN FIRST HALF OF 2018​.  Full Article

Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).  Full Article

Basilea Extends Existing License Agreement With Pfizer For Cresemba
Friday, 1 Dec 2017 

Dec 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER <<>> FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC.BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED.ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES.WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.FOR FY EXPECTS A REDUCED OPERATING LOSS OF APPROXIMATELY CHF 1 MILLION ON AVERAGE PER MONTH.FOR FY SEES LOWER OPERATING EXPENSES.  Full Article

Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - BASILEA PHARMACEUTICA AG ::‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​.  Full Article

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)